Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions

International Journal of Gynecological Cancer

Volumn 15, Issue 1, 2005, Pages 81-87

  Lee, G Y ^a   Kim, Seok Mo ^a,b   Rim, S Y ^a   Choi, H S ^a   Park, C S ^a   Nam, J H ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Cervix cancer; HPV DNA chip test; Human papillomavirus; Hybrid capture II test

Indexed keywords

VACCINE;

ARTICLE; CANCER SCREENING; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DNA MICROARRAY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HYSTEROGRAPHY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; OUTCOMES RESEARCH; PRECANCER; PREVALENCE; PRIORITY JOURNAL; PUNCH BIOPSY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CERVICOGRAPHY; VIRUS TYPING; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; DNA PROBES, HPV; FEMALE; GENOTYPE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS;

EID: 13244291397     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2005.14417.x     Document Type: Article

References (28)

1. Parkin DM, Muir CS, Whelan SL et al. Cancer incidence in five continents. Comparability and Quality of Data. IARC Sci Publ 1992;120:45-173.
2. Papanicolaou G, Traut HF. The Diagnosis of Uterine Cancer by the Vaginal Smear. New York: Commonwealth Fund, 1943.
3. Anderson GH, Boys DA, Benedit JL et al. Organization and the results of the cervical cytology screening programme in Britisch Columbia 1955-85. BMJ 1998;296: 975-8.
4. Spitzer M. Cervical screening adjuncts: recent advances. Am J Obstet Gynecol 1998;179:544-56.
5. Manos MM, Kinney WK, Hurley LB et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
6. National Cancer Institute Workshop. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA 1989;262:931-4.
7. Kim JW, Kang SB, Seo SK et al. Cytologic screening history of 249 patients with cervical cancer. J Korean Cancer Assoc 1998;30:1198-206.
8. Annual report of gynecologic cancer registry program in Korean for 1998 (January 1, 1998-December 31, 1998). Korean Soc Obstetrics Gynecol 2001;144:425-59.
9. Ries L, Miller B, Hankey B. SEER Cancer Static Review 1973-1991. National Cancer Institute, NIH publication no. 94-2789, Bethesda, MD: National Institute of Health, 1994.
10. National Institutes of Health. Consensus development conference. Statement of cervical cancer 1996 April 1-3. Gynecol Oncol 1997;66:351-61.
11. Fetherston WC. False negative cytology in invasive cancer of the cervix. Clin Obstet Gynecol 1983;26:929-37.
12. Mitchell H, Medley G. Differences between Papanicolaou smears with correct and incorrect diagnoses. Cytopathology 1995;6:368-75.
13. Koss LG. Cervical (Pap) smear: new directions. Cancer 1993;71:1406-12.
14. Tezuka F, Oikawa H, Shuki H, Higashiiwai H. Diagnostic efficacy and validity of the Thinprep method cervical cytology. 1996;71:513-8.
15. Hutchinson LM, Isenstein LM, Goodman A et al. Homogenous sampling accounts for the increased diagnostic accuracy using the Thinprep Processor. Am J Clin Pathol 1994;101:215-9.
16. Lachman MF, Cavallo-Calvanese C. Qualification of a typical squamous cells of undetermided significance in an independent laboratory: is it useful or significant? Am J Obstet Gynecol 1998;179:421-9.
17. Lorincz AT, Temple GF, Kurman RJ, Jenson AB, Lancaster WD. Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst 1987;79:671-7.
18. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk association of 15 common anogenital types. Gynecol Oncol 1992;79:328-37.
19. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288:F55-78.
20. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
21. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
22. Lytwyn A, Sellors JW, Mahony JB et al. A comparison of HPV DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial.-HPV effectiveness in low grade Paps (HELP) study, 1 group. CMAJ 2000;163:701-7.
23. Reithmuller D, Gay C, Bertrand X et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture ii and polymerase chain reaction. Diagn Mol Pathol 1999;8:15.
24. Kaufman RH, Adam E, Vonka V. Human papillomavirus infection and cervical carcinoma. Clin Obstet Gynecol 2000;43:363-80.
25. Wallin KL, Wiklund A, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
26. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000;183:561-7.
27. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate and high risk types as triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-7.
28. Solomon D, Schiffman M, Tarone R, ALTS Study Group. Comparison of three management strategies for patients with a typical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.